Attovia Therapeutics (NASDAQ:ATTO) Coverage Initiated at Morgan Stanley

Equities research analysts at Morgan Stanley assumed coverage on shares of Attovia Therapeutics (NASDAQ:ATTO) in a report released on Monday,Benzinga reports. The firm set an “overweight” rating and a $39.00 price target on the stock. Morgan Stanley’s target price would indicate a potential upside of 88.41% from the company’s current price.

Attovia Therapeutics Price Performance

NASDAQ:ATTO opened at $20.70 on Monday. Attovia Therapeutics has a 12 month low of $16.15 and a 12 month high of $24.32.

Insider Transactions at Attovia Therapeutics

In other news, major shareholder Global Strategic Fund I. Venbio bought 382,352 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was purchased at an average price of $17.00 per share, with a total value of $6,499,984.00. Following the transaction, the insider directly owned 4,181,367 shares in the company, valued at approximately $71,083,239. The trade was a 10.06% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Life Sciences Xi L.P. Frazier purchased 588,235 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were purchased at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the completion of the acquisition, the insider directly owned 6,154,213 shares of the company’s stock, valued at approximately $104,621,621. This trade represents a 10.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 2,740,587 shares of company stock worth $47,269,979.

Institutional Trading of Attovia Therapeutics

An institutional investor recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. raised its holdings in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 164,358 shares of the company’s stock after buying an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.